Arrowhead Pharmaceuticals, Inc. (ARWR)
47.15
-2.21
(-4.48%)
USD |
NASDAQ |
Nov 12, 16:00
47.26
+0.11
(+0.23%)
After-Hours: 20:00
Arrowhead Pharmaceuticals Enterprise Value : 6.429B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 6.429B |
| November 11, 2026 | 6.741B |
| November 10, 2026 | 6.690B |
| November 09, 2026 | 6.724B |
| November 06, 2026 | 7.983B |
| November 05, 2026 | 7.884B |
| November 04, 2026 | 8.476B |
| November 03, 2026 | 8.177B |
| November 02, 2026 | 8.182B |
| October 30, 2026 | 8.229B |
| October 29, 2026 | 8.312B |
| October 28, 2026 | 8.272B |
| October 27, 2026 | 8.106B |
| October 26, 2026 | 8.099B |
| October 23, 2026 | 7.963B |
| October 22, 2026 | 8.011B |
| October 21, 2026 | 8.079B |
| October 20, 2026 | 8.090B |
| October 19, 2026 | 7.852B |
| October 16, 2026 | 7.664B |
| October 15, 2026 | 8.031B |
| October 14, 2026 | 8.013B |
| October 13, 2026 | 7.979B |
| October 12, 2026 | 8.346B |
| October 09, 2026 | 8.631B |
| Date | Value |
|---|---|
| October 08, 2026 | 8.347B |
| October 07, 2026 | 8.452B |
| October 06, 2026 | 8.460B |
| October 05, 2026 | 8.575B |
| October 02, 2026 | 8.834B |
| October 01, 2026 | 8.919B |
| September 30, 2026 | 9.012B |
| September 29, 2026 | 9.125B |
| September 28, 2026 | 9.013B |
| September 25, 2026 | 9.078B |
| September 24, 2026 | 9.100B |
| September 23, 2026 | 9.225B |
| September 22, 2026 | 9.917B |
| September 21, 2026 | 9.483B |
| September 18, 2026 | 9.157B |
| September 17, 2026 | 9.335B |
| September 16, 2026 | 9.060B |
| September 15, 2026 | 9.749B |
| September 14, 2026 | 11.16B |
| September 11, 2026 | 11.47B |
| September 10, 2026 | 11.46B |
| September 09, 2026 | 11.44B |
| September 08, 2026 | 11.79B |
| September 04, 2026 | 11.96B |
| September 03, 2026 | 11.98B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Moderna, Inc. | 92.52B |
| Sarepta Therapeutics, Inc. | 1.891B |
| Twist Bioscience Corp. | 7.085B |
| Revolution Medicines, Inc. | 35.70B |
| Immunome, Inc. | 1.675B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -178.92M |
| Revenue (Quarterly) | 75.25M |
| Total Expenses (Quarterly) | 269.53M |
| EPS Diluted (Quarterly) | -1.355 |
| Gross Profit Margin (Quarterly) | 91.15% |
| Profit Margin (Quarterly) | -237.8% |
| Earnings Yield | -4.76% |
| Normalized Earnings Yield | -4.757 |